Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF

SOUTH SAN FRANCISCO, Calif., Sept. 21 /PRNewswire/ -- Takeda San Francisco,
Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company
Limited, announced today that it has entered into a sponsored research
collaboration with the University of California, San Francisco. The research
program will focus on therapeutic antibody discovery and development to an
undisclosed target. The agreement will solely support specific research
conducted in the laboratory of Charles Craik, Ph.D., who will serve as the
principal investigator for the project. This agreement enhances TSF's
initiative to build a robust preclinical antibody therapeutics pipeline by
leveraging the company's comprehensive and proprietary antibody technology
platform and novel discovery, optimization and development technologies.

"This partnership is another example of UCSF's increasing commitment to using
its world-class biomedical research programs to bring direct benefit to
patients," said Dr. Regis Kelly, Executive Director of QB3, the California
Institute for Quantitative Biosciences, one of four California Institutes for
Science and Innovation.

"We're pleased to work with Dr. Craik, who is a leader in the field of
proteases associated with disease pathogenesis," said Dr. Mary Haak-Frendscho,
President and CSO of TSF. "We believe this research will help enable the
discovery and development of a novel antibody product candidate to preclinical
proof of concept. It furthermore demonstrates our commitment to working with
academic experts concerning the development of novel biologic targets for the
treatment of disease."

About Takeda San Francisco, Inc.
Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly
owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is
Takeda's Biologics Center of Excellence and Antibody IND Engine for human
antibody therapeutics for the treatment of cancer, inflammation and metabolic
diseases. TSF supports Takeda's therapeutic antibody initiative in close
collaboration with Takeda's other R&D organizations. Additional information
about Takeda San Francisco is available at http://www.takedasf.com.

About Takeda Pharmaceutical Company, Limited.
Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a
research-based global company with its main focus on pharmaceuticals. As the
largest pharmaceutical company in Japan and one of the global leaders of the
industry, Takeda is committed to striving toward better health for individuals
and progress in medicine by developing superior pharmaceutical products.
Additional information about Takeda is available through its corporate
website, http://www.takeda.com.

About UCSF-Craik Laboratory
Dr. Charles Craik is a Professor of Pharmaceutical Chemistry at UCSF. His
laboratory is focused on the role of protease structure and mechanisms of
essential proteins associated with both normal and dysfunctional biological
processes using novel genetic, biochemical and biophysical methods. Dr. Craik
has pioneered new combinatorial technologies to probe protein-protein
interaction interfaces and identify inhibitors in addition to developing an
array of new expression methods to better address protein structure and
function.

UCSF is a leading university dedicated to promoting health worldwide through
advanced biomedical research, graduate-level education in the life sciences
and health professions, and excellence in patient care. For further
information, please visit www.ucsf.edu.

Disclaimer
The information stated above was prepared by Takeda San Francisco and reflects
solely the opinion of the company. Nothing in this statement shall be
construed to imply any support or endorsement of Takeda, or any of its
products, by The Regents of the University of California, its officers, agents
and employees.

SOURCE Takeda San Francisco, Inc.

Patricia Sinatra, Corporate Communications and Public Relations, Takeda San
Francisco, Inc., +1-650-745-9332